Payment overview · 2025
General Payments
$1,806.79
92 reported records · 28 companies
Healthcare provider profile · identity verified
Purna Sharma
Allopathic & Osteopathic Physicians|Internal Medicine · SEAFORD, DE · NPI 1902391675
Verified facts
What the public records show
CMS Open Payments records show Purna Sharma received $1,806.79 in general payments during 2025 across 92 reported records.
Novo Nordisk Inc accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.26 | 12.6% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.65 | 9.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.37 | 9.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.18 | 8.4% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $104.30 | 5.8% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $97.55 | 5.4% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $94.39 | 5.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.06 | 4.7% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $77.68 | 4.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.85 | 3.4% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $54.13 | 3.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.21 | 2.8% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.01 | 2.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.84 | 2.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.97 | 2.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.22 | 2.1% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$32.89 | 1.8% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $31.09 | 1.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.84 | 1.6% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $25.09 | 1.4% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $24.89 | 1.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.66 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.80 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.48 | 1.1% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $19.79 | 1.1% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$19.65 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.54 | 0.9% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $16.40 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,806.79 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $207.42 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $207.42 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $175.65 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $136.54 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.37 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $104.30 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $104.30 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $94.39 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.33 | 7 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $85.44 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $77.68 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $73.16 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.03 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $60.85 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $54.13 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.21 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $50.01 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.25 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $47.84 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $47.84 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.21 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.21 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.22 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $31.09 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $12.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 117 |
| Lisinopril | Lisinopril | 263 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 75 |
| Losartan Potassium | Losartan Potassium | 199 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 40 |
| Omeprazole | Omeprazole | 162 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 52 |
| Gabapentin | Gabapentin | 157 | 52 |
| Metformin Hcl | Metformin Hcl | 153 | 48 |
| Trazodone Hcl | Trazodone Hcl | 123 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 35 |
| Metformin Hcl Er | Metformin Hcl | 94 | 25 |
| Montelukast Sodium | Montelukast Sodium | 93 | 26 |
| Sertraline Hcl | Sertraline Hcl | 89 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 27 |
| Simvastatin | Simvastatin | 70 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 17 |
| Ezetimibe | Ezetimibe | 63 | 19 |
| Allopurinol | Allopurinol | 60 | 20 |
| Jardiance | Empagliflozin | 56 | 16 |
| Potassium Chloride | Potassium Chloride | 54 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 17 |
| Ozempic | Semaglutide | 49 | 11 |
| Atenolol | Atenolol | 47 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 17 |
| Famotidine | Famotidine | 45 | 16 |
| Meloxicam | Meloxicam | 45 | 15 |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Furosemide | Furosemide | 42 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 13 |
| Carvedilol | Carvedilol | 40 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 14 |
| Alprazolam | Alprazolam | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 11 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Ramipril | Ramipril | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Naproxen | Naproxen | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,806.79 · 92 records | Novo Nordisk Inc | ABRYSVO, ACTHAR, AIRSUPRA, AREXVY, BREZTRI, Briviact, CAPVAXIVE, COMIRNATY, DUPIXENT, FASENRA, GARDASIL 9, Gamunex-C, General - DBS, JARDIANCE, KEVEYIS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, Rystiggo, SHINGRIX, STRENSIQ, TEZSPIRE, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VALTOCO, VOQUEZNA, VRAYLAR, VYEPTI, ZAVZPRET, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error